Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma
Not yet recruitingOBSERVATIONAL
Enrollment
70
Participants
Timeline
Start Date
July 31, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Conditions
Unresectable Liver Cancer
All Listed Sponsors
lead
Yao Xie
OTHER
NCT06715072 - Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter